#1 Hypoglycemia
Insulin Delivery Systems → Hypoglycemia
Evidence Intelligence™
- EvidenceScore™
- 87
- Strong
- ImpactScore™
- 56
- Slightly Positive
- ConsistencyScore™
- 56
- generally_consistent
Estudios de apoyo: Basado en 9 estudios
Explore evidenceSafety
Last updated: 29 de agosto de 2026
Key takeaway
Safety has evidence across 10 diabetes-related interventions, with strongest support for Insulin Delivery Systems, Insulin Therapies and GLP-1 Receptor Agonists.
Evidence status
Extensive ResearchEvidence Base: 81/100
Related Evidence Topics
Evidence Intelligence™
Every evidence topic is generated from structured relationships across diabetes research, including topics, interventions, outcomes, and individual studies.
205
Evidence relationships
224
Studies reviewed
13
Interventions evaluated
Strongest evidence area
Insulin Delivery Systems
Top Evidence Areas
Showing grouped evidence. Expand in Evidence Explorer for detailed intervention-outcome pairs.Open Evidence Explorer
| Rank | Intervention group | Outcome group | EvidenceScore™ | ImpactScore™ | Consistency | Studies | Effectiveness | Action |
|---|---|---|---|---|---|---|---|---|
| #1 | Insulin Delivery Systems | Hypoglycemia | 87/100Strong | 56/100Slightly Positive | 56/100generally_consistent | 9 | weak_positive | Explore evidence |
| #2 | Insulin Therapies | Hypoglycemia | 82/100Strong | 58/100Slightly Positive | 67/100generally_consistent | 6 | weak_positive | Explore evidence |
| #3 | GLP-1 Receptor Agonists | Hypoglycemia | 81/100Strong | 54/100Slightly Positive | 100/100consistent | 12 | weak_positive | Explore evidence |
| #4 | GLP-1 Receptor Agonists | Gastrointestinal Adverse Events | 79/100Strong | 46/100Slightly Negative | 86/100consistent | 7 | weak_negative | Explore evidence |
| #5 | DPP-4 Inhibitors | Hypoglycemia | Moderate | 75/100Positive | 100/100consistent | 2 | moderate_positive | Explore evidence |
| #6 | SGLT2 Inhibitors | Hypoglycemia | Moderate | 50/100Neutral | 100/100consistent | 2 | neutral | Explore evidence |
| #7 | GLP-1 Receptor Agonists | Urinary Tract Infections | 64/100Moderate | 70/100Positive | 35/100mixed | 2 | moderate_positive | Explore evidence |
| #8 | Alpha-glucosidase inhibitors | Hypoglycemia | Emerging | 50/100Neutral | unclear | 1 | neutral | Explore evidence |
| #9 | DPP-4 Inhibitors | Gastrointestinal Adverse Events | Emerging | 50/100Neutral | unclear | 1 | neutral | Explore evidence |
| #10 | Diabetes Self-Management Education and Support (DSMES) Programs | Hypoglycemia | Emerging | 100/100Very Positive | unclear | 1 | strong_positive | Explore evidence |
#2 Hypoglycemia
Insulin Therapies → Hypoglycemia
Evidence Intelligence™
- EvidenceScore™
- 82
- Strong
- ImpactScore™
- 58
- Slightly Positive
- ConsistencyScore™
- 67
- generally_consistent
Estudios de apoyo: Basado en 6 estudios
Explore evidence#3 Hypoglycemia
GLP-1 Receptor Agonists → Hypoglycemia
Evidence Intelligence™
- EvidenceScore™
- 81
- Strong
- ImpactScore™
- 54
- Slightly Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 12 estudios
Explore evidence#4 Gastrointestinal Adverse Events
GLP-1 Receptor Agonists → Gastrointestinal Adverse Events
Evidence Intelligence™
- EvidenceScore™
- 79
- Strong
- ImpactScore™
- 46
- Slightly Negative
- ConsistencyScore™
- 86
- consistent
Estudios de apoyo: Basado en 7 estudios
Explore evidence#5 Hypoglycemia
DPP-4 Inhibitors → Hypoglycemia
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
Explore evidence#6 Hypoglycemia
SGLT2 Inhibitors → Hypoglycemia
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
Explore evidence#7 Urinary Tract Infections
GLP-1 Receptor Agonists → Urinary Tract Infections
Evidence Intelligence™
- EvidenceScore™
- 64
- Moderate
- ImpactScore™
- 70
- Positive
- ConsistencyScore™
- 35
- mixed
Estudios de apoyo: Basado en 2 estudios
Explore evidence#8 Hypoglycemia
Alpha-glucosidase inhibitors → Hypoglycemia
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Explore evidence#9 Gastrointestinal Adverse Events
DPP-4 Inhibitors → Gastrointestinal Adverse Events
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Explore evidence#10 Hypoglycemia
Diabetes Self-Management Education and Support (DSMES) Programs → Hypoglycemia
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Explore evidencePractical Questions
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
Which interventions have the strongest evidence for affecting Safety?
evidence strengthStrong Evidence
Hybrid closed-loop system and Semaglutide have the strongest available evidence signals for Safety.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Hybrid closed-loop system
EvidenceScore™ Strong | EvidenceScore™ 84.7 | neutral | ConsistencyScore™ Generally Consistent | 7 studies
- 2
Semaglutide
EvidenceScore™ Strong | EvidenceScore™ 78.7 | weak positive | ConsistencyScore™ Consistent | 4 studies
Why this answer: This answer is based on 11 supporting studies and existing graph evidence signals.
Limitations
- Population details are unavailable.
Which interventions are most often studied for Safety?
most studiedEmerging Evidence
Insulin degludec, Liraglutide, and Semaglutide are among the most studied areas in relation to Safety.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Semaglutide
EvidenceScore™ Strong | EvidenceScore™ 78.7 | weak positive | ConsistencyScore™ Consistent | 9 studies
- 2
Liraglutide
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Mixed | 7 studies
- 3
Insulin degludec
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 4 studies
Why this answer: This answer is based on 20 supporting studies and existing graph evidence signals.
Limitations
- Consistency cannot yet be determined.
- Population details are unavailable.
Where are results mixed or inconsistent for Safety?
consistency issuesModerate Evidence
Results are mixed or unclear for Insulin therapy and Liraglutide in relation to Safety.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The evidence includes both beneficial and harmful or worsening results.
Ranked evidence signals
- 1
Insulin therapy
EvidenceScore™ Strong | EvidenceScore™ 79.0 | weak positive | ConsistencyScore™ Mixed | 3 studies
- 2
Liraglutide
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Mixed | 4 studies
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Population details are unavailable.
Which interventions need more research for Safety?
research gapsEmerging Evidence
40% dextrose gel (200 mg/kg) and 40% dextrose gel (400 mg/kg) need more research in relation to Safety.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
40% dextrose gel (200 mg/kg)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
- 2
40% dextrose gel (400 mg/kg)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
How does Hybrid closed-loop system compare with Hybrid closed-loop system for Safety?
compareStrong Evidence
Hybrid closed-loop system have available evidence for Safety, but the comparison requires review of the underlying studies.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Hybrid closed-loop system
EvidenceScore™ Strong | EvidenceScore™ 84.7 | neutral | ConsistencyScore™ Generally Consistent | 7 studies
Why this answer: This answer is based on 7 supporting studies and existing graph evidence signals.
Limitations
- Population details are unavailable.
Interventions Studied for Safety
Intervention categories most commonly studied for safety outcomes.
Liraglutide
EvidenceScore™ 62/100
Evidence related to liraglutide and liraglutide-containing intervention regimens in diabetes studies.
10 Studies
GLP-1 Receptor Agonists
EvidenceScore™ 61/100
Evidence related to GLP-1 receptor agonist therapies in diabetes studies.
29 Studies
Insulin Therapies
EvidenceScore™ 60/100
Evidence related to insulin therapies in diabetes studies.
18 Studies
DPP-4 Inhibitors
EvidenceScore™ 59/100
Evidence related to DPP-4 inhibitor therapies in diabetes studies.
8 Studies
Metformin
EvidenceScore™ 59/100
Evidence related to metformin therapies in diabetes studies.
7 Studies
Probiotics and Synbiotics
EvidenceScore™ 59/100
Evidence related to probiotic and synbiotic interventions in diabetes studies.
6 Studies
Latest Research
Mediterranean Ketogenic Diet Shows Comparable Weight Loss to VLCKD
Published: 5 de abril de 2026
int-mediterranean-ketogenic-dietint-very-low-calorie-ketogenic-diet
out-serum-creatinine
Corticosteroids may help manage cytokine release syndrome during teplizumab therapy
Published: 1 de marzo de 2026
int-teplizumab
out-cytokine-release-syndrome
Hybrid closed-loop system improves glycemic control in neonatal diabetes.
Published: 24 de febrero de 2026
int-hybrid-closed-loop-system
out-incidence-of-hypoglycaemia
Artificial pancreas may improve glucose control in type 1 diabetes
Published: 20 de enero de 2026
int-hybrid-closed-loop-systemint-insulin-therapy
out-hypoglycemia-events
Switching to tirzepatide improves glycemic control and weight in type 2 diabetes
Published: 1 de enero de 2026
int-dulaglutide-dose-escalationint-tirzepatide
out-gastrointestinal-disorders-incidenceout-severe-hypoglycemia
Oral Semaglutide Reduces Heart Failure Events in Diabetes
Published: 1 de enero de 2026
int-semaglutide
out-hyperglycemia-eventsout-hypoglycemia-events
Probiotics reduce GI side effects of metformin without improving metabolic efficacy
Published: 1 de enero de 2026
int-multi-species-synbiotic-fos
out-abnormal-stool-frequencyout-gastrointestinal-symptoms-frequency
Cooled Pasta May Reduce Blood Sugar Spikes in Type 1 Diabetes
Published: 1 de enero de 2026
int-cooled-reheated-pastaint-freshly-cooked-pasta
out-frequency-of-hypoglycemic-episodes-at-180-min
Dapagliflozin and Gliclazide Combination Improves Glycemic Control
Published: 1 de enero de 2026
int-dapagliflozinint-dapagliflozin-gliclazide-combination
out-percentage-of-hypoglycemic-events
Efsitora improves HbA1c control compared to degludec in Japanese adults.
Published: 1 de enero de 2026
int-efsitoraint-insulin-degludec
out-severe-hypoglycemia
Evidence Landscape
Evidence landscape
Each bubble represents an evidence relationship. Position shows effectiveness and EvidenceScoreâ„¢; size reflects study volume.
- Strong evidence
- Moderate evidence
- Limited evidence
Evidence Workspace
Create your evidence workspace
Save evidence topics and organize the research that matters to you.